Cargando…

Dynamics of IgG-avidity and antibody levels after Covid-19

BACKGROUND: A potentially important aspect of the humoral immune response to Covid-19 is avidity, the overall binding strength between antibody and antigen. As low avidity is associated with a risk of re- infection in several viral infections, avidity might be of value to predict risk for reinfectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Löfström, Emma, Eringfält, Anna, Kötz, Arne, Wickbom, Fredrik, Tham, Johan, Lingman, Markus, Nygren, Jens M., Undén, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451979/
https://www.ncbi.nlm.nih.gov/pubmed/34563862
http://dx.doi.org/10.1016/j.jcv.2021.104986
_version_ 1784569967783444480
author Löfström, Emma
Eringfält, Anna
Kötz, Arne
Wickbom, Fredrik
Tham, Johan
Lingman, Markus
Nygren, Jens M.
Undén, Johan
author_facet Löfström, Emma
Eringfält, Anna
Kötz, Arne
Wickbom, Fredrik
Tham, Johan
Lingman, Markus
Nygren, Jens M.
Undén, Johan
author_sort Löfström, Emma
collection PubMed
description BACKGROUND: A potentially important aspect of the humoral immune response to Covid-19 is avidity, the overall binding strength between antibody and antigen. As low avidity is associated with a risk of re- infection in several viral infections, avidity might be of value to predict risk for reinfection with covid-19. OBJECTIVES: The purpose of this study was to describe the maturation of IgG avidity and the antibody-levels over time in patients with PCR-confirmed non-severe covid-19. STUDY DESIGN: Prospective longitudinal cohort study including patients with RT-PCR confirmed covid-19. Blood samples were drawn 1, 3 and 6 months after infection. Antibody levels and IgG-avidity were analysed. RESULTS: The majority had detectable s- and n-antibodies (88,1%, 89,1%, N = 75). The level of total n-antibodies significantly increased from 1 to 3 months (median value 28,3 vs 39,3 s/co, p<0.001) and significantly decreased from 3 to 6 months (median value 39,3 vs 17,1 s/co, p<0.001). A significant decrease in the IgG anti-spike levels (median value 37,6, 24,1 and 18,2 RU/ml, p<0.001) as well as a significant increase in the IgG-avidity index (median values 51,6, 66,0 and 71,0%, p<0.001) were seen from 1 to 3 to 6 months. CONCLUSION: We found a significant ongoing increase in avidity maturation after Covid-19 whilst the levels of antibodies were declining, suggesting a possible aspect of long-term immunity.
format Online
Article
Text
id pubmed-8451979
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-84519792021-09-21 Dynamics of IgG-avidity and antibody levels after Covid-19 Löfström, Emma Eringfält, Anna Kötz, Arne Wickbom, Fredrik Tham, Johan Lingman, Markus Nygren, Jens M. Undén, Johan J Clin Virol Article BACKGROUND: A potentially important aspect of the humoral immune response to Covid-19 is avidity, the overall binding strength between antibody and antigen. As low avidity is associated with a risk of re- infection in several viral infections, avidity might be of value to predict risk for reinfection with covid-19. OBJECTIVES: The purpose of this study was to describe the maturation of IgG avidity and the antibody-levels over time in patients with PCR-confirmed non-severe covid-19. STUDY DESIGN: Prospective longitudinal cohort study including patients with RT-PCR confirmed covid-19. Blood samples were drawn 1, 3 and 6 months after infection. Antibody levels and IgG-avidity were analysed. RESULTS: The majority had detectable s- and n-antibodies (88,1%, 89,1%, N = 75). The level of total n-antibodies significantly increased from 1 to 3 months (median value 28,3 vs 39,3 s/co, p<0.001) and significantly decreased from 3 to 6 months (median value 39,3 vs 17,1 s/co, p<0.001). A significant decrease in the IgG anti-spike levels (median value 37,6, 24,1 and 18,2 RU/ml, p<0.001) as well as a significant increase in the IgG-avidity index (median values 51,6, 66,0 and 71,0%, p<0.001) were seen from 1 to 3 to 6 months. CONCLUSION: We found a significant ongoing increase in avidity maturation after Covid-19 whilst the levels of antibodies were declining, suggesting a possible aspect of long-term immunity. The Authors. Published by Elsevier B.V. 2021-11 2021-09-20 /pmc/articles/PMC8451979/ /pubmed/34563862 http://dx.doi.org/10.1016/j.jcv.2021.104986 Text en © 2021 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Löfström, Emma
Eringfält, Anna
Kötz, Arne
Wickbom, Fredrik
Tham, Johan
Lingman, Markus
Nygren, Jens M.
Undén, Johan
Dynamics of IgG-avidity and antibody levels after Covid-19
title Dynamics of IgG-avidity and antibody levels after Covid-19
title_full Dynamics of IgG-avidity and antibody levels after Covid-19
title_fullStr Dynamics of IgG-avidity and antibody levels after Covid-19
title_full_unstemmed Dynamics of IgG-avidity and antibody levels after Covid-19
title_short Dynamics of IgG-avidity and antibody levels after Covid-19
title_sort dynamics of igg-avidity and antibody levels after covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451979/
https://www.ncbi.nlm.nih.gov/pubmed/34563862
http://dx.doi.org/10.1016/j.jcv.2021.104986
work_keys_str_mv AT lofstromemma dynamicsofiggavidityandantibodylevelsaftercovid19
AT eringfaltanna dynamicsofiggavidityandantibodylevelsaftercovid19
AT kotzarne dynamicsofiggavidityandantibodylevelsaftercovid19
AT wickbomfredrik dynamicsofiggavidityandantibodylevelsaftercovid19
AT thamjohan dynamicsofiggavidityandantibodylevelsaftercovid19
AT lingmanmarkus dynamicsofiggavidityandantibodylevelsaftercovid19
AT nygrenjensm dynamicsofiggavidityandantibodylevelsaftercovid19
AT undenjohan dynamicsofiggavidityandantibodylevelsaftercovid19